Special Issue "Molecular and Cellular Mechanisms of CVD: Focus on Atherosclerosis Volume II"
Deadline for manuscript submissions: 31 January 2024 | Viewed by 678
Interests: macrophage; monocyte; chronic inflammation; innate immunity; mitophagy; dysfunctional mitochondria; modified low density lipoprotein; atherosclerosis
Special Issues, Collections and Topics in MDPI journals
The modern inflammatory hypothesis of atherogenesis, which supplemented the classical cholesterol hypothesis, is now generally accepted and suggests the development of an effective therapy aimed at eliminating local chronic inflammation in the vessel wall. Thanks to Anichkov's cholesterol theory, it is well known that the accumulation of intracellular cholesterol in the vascular wall is a trigger for atherogenesis. However, not everything is so simple: approaches aimed at lowering blood cholesterol, LDL receptor regulation or cholesterol efflux showed insufficient effectiveness. However, they significantly improved the life expectancy and quality of life.
Recent advancements in new anti-inflammatory trials aiming to reduce cardiovascular complications only confirm the central role of chronic inflammation in CVD. Additionally, the importance of these trials can hardly be overestimated. The issue of uncovering the mechanisms underlying the chronification of the inflammatory response is now becoming especially urgent.
I think our current achievements are very similar to the success of physicists, hard at work on the Theory of Everything, which would explain the laws of the universe. Despite the complexity of our problem, I believe that humanity is already close to unraveling the underlying mechanisms of diseases, and we will be able to beat atherosclerosis, cancer, aging and, ultimately, death. However, we will then face completely different problems relating the economy, overpopulation and other aspects.
In this Special Issue, I want to collect the most recent publications on the mechanisms of the initiation of atherosclerosis and other age-related diseases. Studies on other important factors, such as lipid metabolism, genetic predisposition, the role of the microbiota, etc., as well as novel therapeutic approaches, are welcome. I also welcome research describing mitochondrial dysfunction, mtDNA mutations and the role of mitochondria in immune response.
Dr. Nikita G. Nikiforov
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cardiovascular diseases
- molecular and cellular mechanisms
- chronic inflammation
- innate immunity
- mitochondrial dysfunction